114 related articles for article (PubMed ID: 28754301)
1. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Aibe N; Shimizu D; Kimoto T; Yamada K; Ueno A; Matsugasumi T; Yamada Y; Shiraishi T; Fujihara A; Okihara K; Yoshida K; Nakamura S
Sci Rep; 2021 Mar; 11(1):6165. PubMed ID: 33731856
[TBL] [Abstract][Full Text] [Related]
4. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.
Moulton CR; House MJ; Lye V; Tang CI; Krawiec M; Joseph DJ; Denham JW; Ebert MA
Radiat Oncol; 2016 Oct; 11(1):144. PubMed ID: 27799048
[TBL] [Abstract][Full Text] [Related]
5. Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M; Thomas SS; Cain A; Palvai S; Nageshwaran S; Zhang J; Hayden K; Cain A; Hoskin P; Ahmed I
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):90-99. PubMed ID: 38163520
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis.
Watanabe K; Kamitani N; Ikeda N; Kawata Y; Tokiya R; Hayashi T; Miyaji Y; Tamada T; Katsui K
Brachytherapy; 2024; 23(2):179-187. PubMed ID: 38245406
[TBL] [Abstract][Full Text] [Related]
7. High-dose-rate brachytherapy as monotherapy versus as boost in unfavorable intermediate-risk localized prostate cancer: A matched-pair analysis.
Willen BD; Salari K; Zureick AH; Lang D; Ye H; Marvin K; Nandalur SR; Krauss DJ
Brachytherapy; 2023; 22(5):571-579. PubMed ID: 37328337
[TBL] [Abstract][Full Text] [Related]
8. A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.
Fischer-Valuck BW; Gay HA; Patel S; Baumann BC; Michalski JM
Front Oncol; 2019; 9():1378. PubMed ID: 31921640
[TBL] [Abstract][Full Text] [Related]
9. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series.
Thomas H; Chen JJ; Abdul-Baki H; Sabbagh A; Shaheen H; Chau OW; Malik N; Ayoub A; Hassanzadeh C; Hsu IC; Mohamad O
Brachytherapy; 2024; 23(2):173-178. PubMed ID: 38160102
[TBL] [Abstract][Full Text] [Related]
10. The evolution of brachytherapy for prostate cancer.
Zaorsky NG; Davis BJ; Nguyen PL; Showalter TN; Hoskin PJ; Yoshioka Y; Morton GC; Horwitz EM
Nat Rev Urol; 2017 Jun; 14(7):415-439. PubMed ID: 28664931
[TBL] [Abstract][Full Text] [Related]
11. Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma.
Lobo S; Gaze MN; Slater O; Hoskin P; Sands G; Sullivan T; Cho A; Eminowicz G; Smeulders N
Pediatr Blood Cancer; 2022 Aug; 69(8):e29574. PubMed ID: 35044080
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy at 3 Gy per fraction for lip carcinoma: Treatment outcomes and toxicity at 5-years.
Tuček L; Sirák I; Hodek M; Kašaová L; Grepl J; Paluska P; Pohanková D; Hruška L; Vošmik M; Petera J
Brachytherapy; 2023; 22(4):496-502. PubMed ID: 37015847
[TBL] [Abstract][Full Text] [Related]
13. Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review.
Dornisch AM; Zhong AY; Poon DMC; Tree AC; Seibert TM
World J Urol; 2024 Jan; 42(1):56. PubMed ID: 38244059
[TBL] [Abstract][Full Text] [Related]
14. Thermally boosted interstitial high-dose-rate brachytherapy in high-risk early-stage breast cancer conserving therapy - large cohort long-term results.
Chicheł A; Burchardt WM; Kluska A; Chyrek AJ
Rep Pract Oncol Radiother; 2023; 28(5):661-670. PubMed ID: 38179295
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiotherapy Combined with Brachytherapy for the Definitive Treatment of Esophageal Carcinoma.
Mangesius J; Hörmandinger K; Jäger R; Skvortsov S; Plankensteiner M; Maffei M; Seppi T; Dejaco D; Santer M; Sarcletti M; Ganswindt U
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509257
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study.
Hass P; Fischbach F; Pech M; Gawish A
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5397-5404. PubMed ID: 36445477
[TBL] [Abstract][Full Text] [Related]
17. The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments.
Varela Cagetti L; Moureau-Zabotto L; Zemmour C; Ferré M; Giovaninni M; Poizat F; Lelong B; De Chaisemartin C; Mitry E; Tyran M; Zioueche-Mottet A; Salem N; Tallet A
Brachytherapy; 2023; 22(4):531-541. PubMed ID: 37150739
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis.
Miyajima K; Sato S; Uchida N; Suzuki H; Iwatani K; Imai Y; Aikawa K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Honda M; Koike Y; Miki J; Miki K; Shimomura T; Yuen S; Yamada Y; Aoki M; Takahashi H; Urabe F; Kimura T
Clin Genitourin Cancer; 2024 Apr; 22(2):149-156.e1. PubMed ID: 38007354
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center.
Díaz-Gavela AA; Cerro Peñalver ED; Sanchez-Garcia S; Pardo-Perez E; Thuissard-Vasallo IJ; Andreu-Vázquez C; Molina López MY; Pena Huertas M; Guerrero-Gómez LL; Sanz-Rosa D; Lorenzo FC
Brachytherapy; 2024 Mar; ():. PubMed ID: 38522961
[TBL] [Abstract][Full Text] [Related]
20. High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms.
Dabic-Stankovic K; Rajkovic K; Stankovic J; Marosevic G; Kolarevic G; Pavicar B
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):378-389. PubMed ID: 38584072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
